Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 4

Arterial Stiffness and Pharmacological Interventions – The TRanscend Arterial stiffNess Substudy (TRANS study)

Authors Jirar Topouchian, Ramzi El Feghali, Bruno Pannier, Shuyu Wang, Feng Zhao, Karel Smetana, Koon Teo, Roland Asmar

Published 15 September 2007 Volume 2007:3(4) Pages 381—388

Jirar Topouchian1, Ramzi El Feghali1, Bruno Pannier1, Shuyu Wang2, Feng Zhao3, Karel Smetana4, Koon Teo3, Roland Asmar1

1The CardioVascular Institute, Paris, France; 2Beijing Clinical Trial and Research Center, Beijing, China; 3Population Health Research Institute, Hamilton, Canada; 4Vojenska nemocnice Plzen, Pizen, Czech Republic

Abstract: The degree of arterial stiffness is correlated with the risk of cardiovascular diseases and it is a powerful predictor for morbidity and mortality. Studies have shown that arterial stiffness reduction is associated with an improvement in survival. Reduction of arterial stiffness by pharmacological drugs varies according to the drugs and doses used and duration of treatment. This effect on the arteries differs among the various classes of drugs and among individual drugs in the same class. Quantification of the stiffness and other properties of the arterial wall can be used to monitor the responses to therapy in individuals with hypertension and other cardiovascular diseases. These measures can then be used as surrogate markers for the risk of clinical events. Inhibition of the renin-angiotensin system (RAS) is associated with an important decrease in cardiovascular risk. Findings from clinical trials support the hypothesis that the protective effects of RAS inhibition are partly independent from blood pressure reduction and related to several mechanisms including vascular protective effects. The aim of the TRanscend Arterial stiffNess Substudy (TRANS) is to assess the effect of an angiotensin II receptor blocker (ARB), telmisartan, on the arterial stiffness in a subgroup of patients from the Telmisartan Randomized Assessment Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trial. The TRANSCEND trial is an international, multicenter, randomized double blind placebo controlled trial of telmisartan that enrolled patients at high risk for cardiovascular events. Some clinical baseline data of the TRANS substudy are reported. When completed, the results of the TRANS substudy will show whether the beneficial effects of treatment with telmisartan on cardiovascular outcome may be related to an improvement in arterial stiffness.

Keywords: arterial stiffness, cardiovascular prevention, ARBs, telmisartan, pulse wave velocity, antihypertensive

Download Article [PDF] 

Readers of this article also read:

Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model

Roy K, Kanwar RK, Krishnakumar S, Cheung CH, Kanwar JR

International Journal of Nanomedicine 2015, 10:1019-1043

Published Date: 2 February 2015

Adult nontwin sib concordance rates for type 2 diabetes, hypertension and metabolic syndrome among Asian Indians: The Indian Atherosclerosis Research Study

Jayashree Shanker, Saikat Kanjilal, Veena S Rao, Ganapathy Perumal, Natesha B Khadrinarasimhiah, et al

Vascular Health and Risk Management 2007, 3:1063-1068

Published Date: 15 January 2008

Acute coronary syndrome associated with Churg-Strauss syndrome

Annette Doris Wagner, Gerd Peter Meyer, Markus Rihl, Anke Rathmann, Ulrike Wittkop, et al

Vascular Health and Risk Management 2007, 3:775-779

Published Date: 15 November 2007

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes

Mozhgan Dorkhan, Anders Frid

Vascular Health and Risk Management 2007, 3:721-731

Published Date: 15 November 2007

Bisoprolol in the treatment of chronic heart failure

Pascal de Groote, Pierre-Vladimir Ennezat, Fréderic Mouquet

Vascular Health and Risk Management 2007, 3:431-439

Published Date: 15 September 2007

Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes

John M Stafford, Tom Elasy

Vascular Health and Risk Management 2007, 3:503-510

Published Date: 15 September 2007

Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy

Roland Asmar, Juan Garcia-Puig, Philippe Gosse, Yuri A Karpov, Peter Wilhem De Leeuw, Dieter Magometschniggs, Lajos Matos, Roland Schmieder

Vascular Health and Risk Management 2007, 3:371-380

Published Date: 15 September 2007

Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients

Ana T Rocha, Edison F Paiva, Arnaldo Lichtenstein, Rodolfo Milani Jr, Cyrillo Cavalheiro-Filho,
Francisco H Maffei

Vascular Health and Risk Management 2007, 3:533-553

Published Date: 15 September 2007

Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus

Toshihiro Tsuruda, Johji Kato, Takahiro Sumi, Kazuya Mishima, Hiroyuki Masuyama, Hiroyuki Nakao, Takuroh Imamura, Tanenao Eto, Kazuo Kitamura

Vascular Health and Risk Management 2007, 3:417-423

Published Date: 15 September 2007